STEVEN D REICH, M.D.
Osteopathic Medicine at Stratford Park Cir, Del Mar, CA

License number
California 45007
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
202 Stratford Park Cir, Del Mar, CA 92014
Phone
(858) 755-1732

Organization information

See more information about STEVEN D REICH at bizstanding.com

Steven D Reich MD

202 Stratford Park Cir, Del Mar, CA 92014

Categories:
Emergency & Critical Care Physicians & Surgeons
Phone:
(858) 755-1732 (Phone)

Professional information

Steven D Reich Photo 1

Dr. Steven D Reich, Del Mar CA - MD (Doctor of Medicine)

Specialties:
Oncology, Medical Oncology
Address:
202 Stratford Park Cir, Del Mar 92014
(858) 755-1732 (Phone)
Certifications:
Internal Medicine, 1974, Medical Oncology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Boston U Hosp
Baltimore Cancer Rsch Ctr


Steven Reich Photo 2

Therapeutic Combinations Comprising Poly (Adp-Ribose) Polymerases Inhibitor

US Patent:
2006007, Apr 6, 2006
Filed:
Sep 20, 2005
Appl. No.:
11/231470
Inventors:
Heidi Marie Steinfeldt - San Diego CA, US
Theodore James Boritzki - San Diego CA, US
Alan Hilary Calvert - Blaydon-on-Tyne, GB
Nicola Jane Curtin - Rowlands Gill, GB
Mohamed Raza Dewji - Harrow, GB
Zdenek Hostomsky - La Jolla CA, US
Christopher Jones - Gosforth, GB
Rhonda Kaufman - Bridgewater NJ, US
Karen Klamerus - San Diego CA, US
David Richard Newell - Humshaugh, GB
Elizabeth Ruth Plummer - Heddon-on-the-Wall, GB
Steven Reich - Del Mar CA, US
Ian Stratford - Manchester, GB
Huw David Thomas - Houghton-le-Spring, GB
Kay Janine Williams - Middleton, GB
International Classification:
A61K 31/55
US Classification:
514212060
Abstract:
This invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer.